The global Non-Alcoholic Steatohepatitis Treatment Market was valued at $7.70 billion in 2024 and is projected to reach $55.52 billion by 2032 with a CAGR of 28.05% from 2025 to 2032. The U.S. NASH treatment market is forecast to rise to $32.55 billion by 2032 with a CAGR of 27.88%. Market growth is driven by obesity, diabetes, and metabolic syndrome.

Non-Alcoholic Steatohepatitis is a critical global liver health challenge with limited approved therapies and a growing patient population. Pharmaceutical innovators and researchers are developing new treatments targeting inflammation, fibrosis, and metabolic pathways. Late-stage trials and regulatory pathways are accelerating the shift towards NASH therapeutics.

The Vitamin E and pioglitazone segment dominated the NASH treatment market in 2024, with semaglutide expected to show the fastest growth. NASH Stage F1 accounted for 35% of the market share in 2024, with NASH Stage F0 projected for rapid growth. Hospital pharmacies held a 62% market share in 2024.

North America had a 78% market share in 2024, driven by metabolic risk factors like obesity and diabetes. The Asia Pacific region is expected to experience the fastest CAGR of 30.2%. In August 2024, Shilpa Medicare’s shares surged following positive Phase 3 trial results for NorUDCA, a potential NAFLD treatment.

Exclusive sections of the report include information on prescription trends, pharmaceutical volume, healthcare spending, diagnostic trends, technology adoption, and the competitive landscape. The report also offers related reports on Type 2 Diabetes, Liver Disease Diagnostics, GLP-1 Receptor Agonists, Metabolic Disorder Therapeutics, and Anti-Obesity Drugs. SNS Insider aims to provide clients with accurate market data and insights for confident decision-making.

Read more at GlobeNewswire: Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size